PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031\*\*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Continuation of 09/096,572 **Application Number** INFORMATION DISCLOSURE **Filing Date** June 12, 1998 STATEMENT BY APPLICANT Evans, Christopher H First Named Inventor 37 4833 16 Group Art Unit (use as many sheets as necessary) **Examiner Name** Wilsen, Michael C. Lo. 018484-002121US Sheet Attorney Docket Number

				U.S. PATENT DOCUM	MENTS	
Examiner Initials		U.S. Pa	itent Document			Pages, Columns, Lines,
	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
レメ	AA	5,081,	228	Dower et al.	01/14/1992	
1	AB	5,180,	312	Dower et al.	01/19/1993	
1	AC	5,319,	071	Dower et al.	06/07/1994	
	AD	5,334,	380	Kilbourn et al.	08//02/1994	
	AE	5,350,	383	Sims et al.	09/27/1994	
-	AF	5,399,	346	Anderson et al.	3/1995	

				FOREIG	N PATENT DOCU	MENTS		
	Cita	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T <sup>©</sup>
LOL	AG	WIPO	91 17184	Α	The Upjohn Co.	11/14/1991		
1	AH	WIPO	92 11359	Α	Univ. of Pittsburgh, etc.	07/09/1992		
	Al	WIPO	92 07943			05/1992		
V	AJ.	WIPO	94 20517	Α	Univ. of Pittsburgh, etc.	09/15/1994		

Examiner Signature Date Considered 5.17.05

EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/S8/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
WEADNATION DIOO! ACUEDE	Application Number	09/096,572	4
INFORMATION DISCLOSURE	Filing Date	June 12, 1998	8909
STATEMENT BY APPLICANT	First Named Inventor		95
	Group Art Unit	1633	36
(use as many sheets as necessary)	Examiner Name	Wilson, Michael C.	-
Sheet 2 of	Attorney Docket Number	018484-002120US	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	<del></del>
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т:
FUL	AK	Aderka et al., Arthrit. & Rheum., 36(8):1111-1120 (09/1993)	
	AL	Allen, et al., J. Immunol., 151:4344-4351 (1993)	
1	АМ	Anderson et al., Human Gene Therapy, 1:331-382 (1990)	
	AN	Arend et al., J. Clin. Invest., 88:1445-1451 (1991)	
	AO	Arend, Advances in Immunology, 54:167-227 (1993)	
	AP	Balavoine et al., J. Clin. Invest., 78:1120-1124 (1986)	
	AQ	Bandara et al., Arthrit. & Rheum., 35(9):S193 (#C161) (09/1992)	
	AR	Bandara et al., DNA Cell Biol., 11:227-231 (1992)	
	AS	Bandara et al., Gene Transfer to Syngvium, 39th Annual Meeting, Orthopaedic Research Society, p. 242	
	AT	Bandara et al., Proc. Natl. Acad. Sci. USA, 90(22):10764-10768 (11/15/1993)	
	BA	Bendara et al., Transplantatin Proceedings, 24(6):2968 (1992)	
	68	Bandare et al., 1992, Nature, 247:1485-1488 (1990)	
	вс	Bandara, G., et al., J. Cell. Biocham., Supplement, 0(17), part E:224, XP000566581 (04/12-18/93)	
	BD	Вал et al., <i>Science</i> , 254:1507-1509 (1991)	
Ÿ	BE	Beaulleu, et al., Arthritis & Rheumatism, 37(6):855-859 (06/1994)	Ī

	1	<u> </u>		
Examiner Signature		1	Date Considered	5.17.05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1319991 v1

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Su	Substitute for form 1449B/PTO		Complete if Known			
	INFORMATION DISCLOSURE		Application Number	09/096,572		
	INFORMATION DISCLOSURE			Filing Date	June 12, 1998	
S	STATEMENT BY APPLICANT		First Named Inventor	·		
			•	Group Art Unit	1633	
	(use as many sheets as necessary)			Examiner Name	Wilson, Michael C.	
SI	heet	3	of	Attorney Docket Number	018484-002120US	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
ry	8F	Bessis, et al., <i>Presse Medicale</i> , 27:580-582 (03/29/98)	
1	BG	Biotechnology News, 14(20):1-12 (08/25/94)	
	вн	Bodgan et al., J. Exp. Med., 174:1549-1555 (1991)	
	Bi	Brouckaert, et al., Eur. J. Immunol., 22:981-986 (1992)	
	BJ	Carter et al., Nature, 344(6267):633-638 (04/12/1990)	
	BK	Conti, P., et al., Immunology, 77:245-250 (1992)	
	BL	Danos and Mulligan, PNAS, 85:8460-8464 (1988)	
	ВМ	Dayer et al., J. Clin. Invest., 77:845-648 (1988)	
	8N	Dayer et al., J. Exp. Med., 182:2163-2168 (1985)	
	во	de Waai Malefyt et al., <i>J. Exp. Med.</i> , 174:1209-1220 (1991)	
	ВР	Deleuran et al., British Journal of Rheum., 31:801-809 (1992)	
	BQ	Denning et al., FASEB J., 3:A785 (#3243) (1989)	
	8R	Dia et al., PNAS, 89:10892-10895 (1992)	
	88	Dinarello and Thompson, Immunology Today, 12 (11):404-410 (1991)	
Y	BT	Dinarello et al., JAMA, 269:1829-1835 (1993)	

Date Examiner Considered Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1319991 v1



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	ute for form 144	9B/PTO	•	Complete if Known	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/096,572	
			Litting pare	June 12, 1998	
STA			First Named Inventor		
			Group Art Unit	1633	
	(use as many sheets as necessary)		Examiner Name	Wilson, Michael C.	
Sheet	4	of	Attorney Docket Number	018484-002120US	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
ight	BU	Docherty and Murphy, Ann. Rheum Dis., 49:469-479 (1990)	
Ì	B∨	Eisenberg et al., <i>Nature</i> , <b>343</b> :341-346 (1990)	
	BW	Englemann et al., J. Biol. Chem., 264:11974-11980 (1989)	
	вх	Essner et al., <i>J. Immunol.</i> , <b>142</b> :3857-3861 (1989)	
	BY	Evans et al., J. Cell. Biochem. Supp. 17E, 0:16:48 (Abstract No. 207) (04/3-91992)	
	BZ	Evans, C., et al., Receptor, 4(1):9-15 (1994)	
	BAA	Fanslow et al., Science, 248:739-742	
	888	Firestein, G. S., et al., <i>J. Immunology</i> , 149(3): 1054-1062 (08/01/1992)	
	ВСС	Firestein, G., S., et al., Curr. Op. Rheum., 10:238-241 (1998)	
	BDD	Firestein, G. S., et al., Arthritis & Rheumatism, 37(5):844-652 (05/1994)	
	BEE	Forentino et al., J. Immunology, 147:3815-3822 (1991)	
	BFF	Fox, et al., Am. J. Med., 99:82-88 (07/95)	
	BGG	Galea-Lauri et al., J. Cell Biochem. Supp. 17E., 224(SZ101) (1993)	
/	внн	Galea-Lauri et al., J. Cell. Blochem. Supp. 17E., 236 (#SZ307)	
J	ВИ	Gatanga et al., Lymphokine Res., 9(2):225-229 (1990)	

Examiner Signature	2	T.	Date Considered	017,	05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1319991 v1



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-00) Approved for use through 10/31/2002 OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 14498/PTO	Complete If Known			
WEADILATION DIOOLOGIST	Application Number	09/096,572		
INFORMATION DISCLOSURE	Filing Date	June 12, 1998		
STATEMENT BY APPLICANT	First Named Inventor			
	Group Art Unit	1633		
(use as many sheets as nacessary)	Examiner Name	Wilson, Michael C.		
Sheet 5 of	Attomey Docket Number	018484-002120US		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	<del>,</del>
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
M	ອມ	Gerald J. Prud'homme, J. Gene Med., 2:222-232 (2000)	
j	ВКК	Granowitz, et al., <i>Blood</i> , 79(9):2358-2363 (1992)	
	BLL	Gutierrez, et al., Lancet, 339:715-721 (03/21/92)	
	вмм	Hannum et at., Nature, 343:338-340 (1990)	
	BNN	Hart, et al., Proc. Natl. Acad. Sci. USA, 86:3803-3807 (5/1989)	
	800	Heilig et al., Clin. Immunology, 13(5): 321-328 (1993)	
	8PP	Houri, et al., Curr. Op. Rheum., 7:201-205 (05/95)	
	BQQ	Howard and O'Garra, Immunology Today, 13:198-200 (1992)	
	BRR	Hung, G. L., et al., Arthritis and Rheum., 36(9):S46 (Supplement) XP 000565750 (9/1993)	
	BSS	Ignotz and Massague, J. Biol. Chem., 261:4337-4345 (1986)	
	втт	ligo et al., J. Immunol., 147:4167-4171 (1991)	
	BUU	Ingontz and Massagua, Cell, 51:189-197 (1987)	
	BVV	Joosten, et al., Ann. Rheum. Dis., 59:196-205 (2000)	
	BWW	Karlsson et al., Bone Marrow Transplantation, 11:124-127 (1993)	
a	вхх	Koch et al., Clinical Immunology and Immunopathology, 65(1):23-29 (10/1992)	

EXAMINER: Initial if reference considered, whether ar not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1319991 v1



Examiner Signature

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

Substitu	ite for form 1449B/PT	0	Complete if Known		
			Application Number	09/096,572	
****	<del>-</del>	DISCLOSURE	Filing Date	June 12, 1998	
STA	TEMENT B	Y APPLICANT	First Named Inventor		
			Group Art Unit	1633	
	(use as many sh	eets as necessary)	Examiner Name	Wilson, Michael C.	
Sheet	6	of	Attorney Docket Number	018484-002120US	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
12	CA	Larrick, Immunology Today, 10(2):61-66 (1989)				
i	СВ	Libert, et al., "Induction of Interleukin 6 by Human and Murine Recombinant Interleukin 1 in mice," Eur. J. Immunol., 20:691-694 (1990)				
	сс	Lombard et al., Arthrit. and Rheum., 36(4):485-489 (1993)				
	CD	Lubberts, et al., <i>J. Immunol.</i> , 163:4548-4558 (1999)				
	CE	Ma, et al., <i>J. Immunol.</i> , 161:1516-1524 (1998)				
	CF	Malyak, M., et al., Arthritis and Rheum, 36(6):781-789 (06/1993)				
	CG	Manthorpe et al., Human Gene Therapy, 4:119-131 (1993)				
	СН	McColl et al., J. Exp. Med., 176:593-598 (08/1992)				
	Ci	McQuillan et al., <i>Biochem. J.</i> , <b>240</b> :423—430 (1986)				
	ಬ	Miller, Retroviral Vectors, Current Topics in Micro-biology and Immunology, 158:1-24 (1992)				
	ск	Morales and Roberts, <i>J. Biol. Chem.</i> , <b>263</b> :12828-12831 (1988)				
	CL	Mulligan, Science, 260:926-931 (1993)				
1	СМ	Mulligan, Science, 260:926-932 (1993)				
/	CN	Nabel et al., Science, 249:1285-1288 (09/14/1990)				
M	со	Nienhaus et al., Cancer 67(10):2700-2704 (1991)				

Examiner Signature		Date Considered	5.17.05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known **Application Number** 09/096,572 INFORMATION DISCLOSURE **Filing Date** June 12, 1998 STATEMENT BY APPLICANT First Named Inventor Group Art Unit 1633 (use as many sheets as necessary) **Examiner Name** Wilson, Michael C. 018484-002120US Sheet of Attorney Docket Number

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
CDL	СР	Nienhuis, et al., "Gene Transfer Into Hematopoietic Stem Cells," Cancer, 67(10):2700-2704 (05/15/91)	
1	ca	Ohashi et al., PNAS, 89:11332-11336 (1992)	
	CR	Ohashi et al., Proc. Natl. Acad. Sci. USA. 89:11332-11338 (1992)	
	cs	Orkin, et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," (1995)	
	ст	Pahan, et al., <i>J Neurochem.</i> , 75(2):576-582 (2000)	
	CU	Raz et al., PNAS, 90:4523-1527 (1993)	
	cv	Robbins, et al., Gene Therapy for Neoplastic Diseases; Annals of the New York Academy of Sciences, Edited by Brian Huber and John Lazo, 716:72-89	
	cw	Robbins, et al., Annals of the New York Academy of Sciences, 716:72-89 (06/29/93)	
	СХ	Roessler et al., J. Clin. Invest., 92:1085-1092 (08/1993)	
	CY	Ronald G. Crystal, Science, 270:404-410 (10/20/95)	
	cz	Ross, et al., <i>Human Gene Therapy</i> , 7:1781-1790 (9/96)	
	CAA	Roux-Lombard, P., et al., Arthritis and Rhaum., 36(4):485-489 (04/1993)	
	CBB	Seitz, et al., J. Immunol., 152:2060-2065 (1994)	
/	ccc	Shalaby, et al., Clinical Immunology and Immunopathology, 53:488-498 (1989)	
V	CDD	Skaleric et al., J. Immunol., 147:2559-2564 (1991)	

	/ \		
Examiner Signature	+	Date Considered	5.17.05

EXAMINER: Initial if reference considered, Whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known		
	Application Number	09/096,572		
INFORMATION DISCLOSURE	Filing Date	June 12, 1998		
STATEMENT BY APPLICANT	First Named Inventor			
	Group Art Unit	1633		
(use as many sheets as necessary)	Examiner Name	Wilson, Michael C.		
Sheet 8 of	Attorney Docket Number	018484-002120US		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	<del></del>
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
LOI	CEE	Smolen et al., J. Immunology, 150(8) Part 2:298A (1993), Abstract No. 1704	
	CFF	Streeter et al., Nature, 331:4 1-46 (1988)	
	cee	Vannier et al., PNAS, 89:4076-4080 (1992)	
	СНН	Weinblatt, Journal of Rheumatology, 19(Sup.32):85-91 (1992)	
1/	Cii	Wooley, et al., Arthritis & Rheumatism, 36(9):1305-1314 (09/93)	
A.	cn	Yang, Critical Reviews in Biochem., 12(4):335-356 (1992)	

	<u>'</u>	1		
Examiner Signature		M	Date Considered	517.05
		7		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1319991 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.